GRAIL Inc. (GRAL)

NASDAQ: GRAL · Real-Time Price · USD

32.52

-1.97 (-5.73%)

At close: May 01, 2025, 3:59 PM

33.00

1.49%

After-hours: May 01, 2025, 06:10 PM EDT

-5.73% (1D)

Bid	32.17
Market Cap	1.15B
Revenue (ttm)	125.59M
Net Income (ttm)	-2.03B
EPS (ttm)	-63.54
PE Ratio (ttm)	-0.51
Forward PE	-1.9
Analyst	Hold

Ask	35.8
Volume	1,185,652
Avg. Volume (20D)	1,516,055
Open	35.13
Previous Close	34.49
Day's Range	32.50 - 35.71
52-Week Range	12.33 - 63.99
Beta	4.93

About GRAL

GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated ...

Sector Healthcare

IPO Date Jun 12, 2024

Employees 1,000

Stock Exchange NASDAQ

Ticker Symbol GRAL

Website https://grail.com

Full Company Profile

Analyst Forecast

According to 3 analyst ratings, the average rating for GRAL stock is "Hold." The 12-month stock price forecast is $26, which is a decrease of -20.04% from the latest price.

Stock Forecasts

Why Price Moved

2 months ago

-14.72%

GRAIL shares are trading lower. The company report... Unlock content with Pro Subscription

2 months ago

-9.2%

GRAIL shares are trading higher after the company reported a year-over-year increase in Q4 financial results.

News

1 week ago · barrons.com

This Cancer Test Could Become Routine—and a Big Seller, Says Analyst

Grail stock will increase at least 20% over the next year, projects Canaccord's Kyle Gibson.

2 weeks ago · seekingalpha.com

GRAIL's Galleri Progresses While Back In Accumulation Levels

GRAL's Galleri test is easily its main value driver at this point. This test can screen over 50 cancers with high sensitivity and accuracy. Post-spin-off from Illumina, GRAL has continued growing its ...

3 weeks ago · seekingalpha.com

How Does GRAIL Benefit From The Proposed MCED Legislation?

GRAIL, Inc.'s Galleri test could see significant revenue growth if the bipartisan MCED bill passes, enabling Medicare reimbursement for FDA-approved multi-cancer early detection tests. Galleri's poten...

2 months ago · seekingalpha.com

GRAIL, Inc. (GRAL) Q4 2024 Earnings Call Transcript

GRAIL, Inc. (NASDAQ:GRAL ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Bob Ragusa - Chief Executive Officer and Board Member Aaron Freidin - Chief Financial Offi...